DepoFoam encapsulates drugs, preserving their molecular structure, and releases them over a desired period of time
How DepoFoam works
The DepoFoam carrier matrix consists of microscopic, spherical, lipid-based particles composed of a honeycomb of numerous, non-concentric, internal aqueous chambers containing the encapsulated drug. Each chamber is separated from adjacent chambers by lipid membranes. Following injection, the DepoFoam particles release the drug over an extended period of time due to erosion and/or reorganization of the lipid membranes.
- DepoFoam offers flexible delivery and can be designed to offer an immediate-release dose followed by sustained delivery
- The ready-to-use aqueous solution works with narrow gauge needles and pen systems
- DepoFoam membrane components are natural, well-tolerated, and cleared by normal metabolic pathways
- DepoFoam permits systemic delivery of medications by releasing the drug into the bloodstream via the interstitial space
- Locally, DepoFoam can release the drug into a body compartment, such as a wound
of naturally occurring, biodegradable and biocompatible lipids2-4
bupivacaine in a multivesicular liposomal drug delivery technology
bupivacaine over time as lipid membranes reorganize1
membrane components that are cleared by normal metabolic pathways2,3
Our DepoFoam extended-release drug delivery technology can be applied to both small and large molecules, potentially improving patient care by providing a unique solution for medications that:
- Need to be administered by continuous infusion or frequent multiple injections
- Have a short duration of action or problematic side effects associated with peak concentrations
We have demonstrated that small and large molecule compounds can successfully be encapsulated into DepoFoam, including:
- Traditional injectable pharmaceuticals
- Antisense oligonucleotides
We are leveraging the proven safety, flexibility, and customizability of our DepoFoam technology for acute, sub-acute, and chronic pain applications. The current opioid crisis was triggered by a pain epidemic. Eliminating opioids will not address the significant unmet need for new tools and strategic approaches for managing pain. We have selected two DepoFoam-based programs for clinical development.
The first is the intrathecal or subarachnoid delivery of a DepoFoam-based local anesthetic other than bupivacaine for acute and chronic pain. We believe this approach may provide an alternative to the use of intrathecal or subarachnoid opioids typically delivered by pumps and catheters.
The second clinical compound we have selected is DepoDexmedetomidine. With this product, we see the target market as end-of-life pain and painful conditions in the elderly. We believe the extended delivery of a therapeutic dose of dexmedetomidine has the potential to offer patients mental acuity and quality of life while also providing adequate pain control.